Diasome Pharmaceuticals Names Sangeeta Sawhney Chief Medical Officer and Expands Leadership as It Prepares HDV-Insulin for Phase 3
Diasome Pharmaceuticals announced on Tuesday, September 15, 2026 that it appointed Sangeeta Sawhney, M.D., as Chief Medical Officer as it prepares its lead program, HDV-Insulin, for Phase 3 development. Paul Strumph, M.D., who had been interim CMO, becomes senior medical advisor, and the company also named Linda Rubinstein chief financial officer, David Williams chief strategy officer, Karen Donovan head of commercial development, and David O'Reilly head of business development. Diasome says HDV-Insulin is designed to restore the liver's role in mealtime insulin action and improve the balance between glucose control and hypoglycemia risk. The announcement said the Phase 2b OPTI-2 trial had concluded but did not report its results or a Phase 3 timeline.